Objective: This study aims to describe the fi nal adult height (FAH) and pubertal growth patterns in human immunodeficiency virus (HIV)-infected adolescents and to compare these to an age-matched population of seroreverting HIV-exposed, uninfected (HEU) adolescents. It further aims to evaluate the interplay of proinfl ammatory cytokines with insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and IGFBP-1 during the pubertal growth spurt. Methods: HIV-infected (n = 34) and HEU (n = 12) adolescents who had achieved FAH were evaluated. Auxologic data, viral load, CD4 + T-lymphocyte (CD4) count, and the use of highly active antiretroviral therapy were obtained via a retrospective chart review. Serum interleukin (IL)-1 α , IL-6, tumor necrosis factor (TNF)-α , IGFBP-1, IGFBP-3, and IGF-1 were assessed. Results: The mean FAH standard deviation score for the HIVinfected group was -0.78 ( ± 1.1) compared to 0.05 ( ± 0.78) for the HEU (p = 0.034). There was a positive correlation between CD4 count and FAH (p = 0.019). The mean age and magnitude of peak growth velocity (GV) was within normal limits. IL-1 α , IL-6, TNF-α , IGFBP-3, and IGF-1 were not significantly correlated with HIV RNA or height. IGFBP-1 was detectable in 100 % of poorly controlled HIV-infected patients and 25 % of the HEU cohort (p = 0.0003).
Introduction
Since the recognition of the human immunodefi ciency virus (HIV) in pediatrics in 1983, the growth of infected children has been studied extensively. Failure to thrive was a feature of the earliest cases of pediatric acquired immunodefi ciency syndrome (AIDS) (1) . Proposed etiologies included chronic illness, malnutrition, AIDS-related enteropathy, increased tissue catabolism, and pubertal delay (2) . With the availability of highly active antiretroviral therapy (HAART) in children in 1996, the disease-related morbidity and mortality decreased considerably. HIV infection changed from a life-threatening illness to a chronic disease. Despite such progress, the height standard deviation score (SDS) of HIV-infected children remains relatively stable, and signifi cantly below that of either age-matched controls or midparental height (3) .
Prior to HAART, the Hemophilia Growth and Development Study found a mean height SDS of -0.56 ( ± 1.23) in those children with both HIV and hemophilia compared to a height SDS -0.01 ( ± 1.18) in the HIV-negative group (p = 0.0001) (2) . Multiple studies subsequently examined the effect of HAART on growth with mixed results. Guill é n et al. (4) examined 212 predominantly prepubertal (median age = 6 years), perinatally infected HIV-infected children over a period of 5 years. HAART was associated with an increase in height SDS from -0.5 to -0.4 (p = 0.008). In contrast, Nachman et al. (5) showed no statistically signifi cant improvement in height or weight in 197 prepubertal patients (median age = 7.2 years; 82 % of patients is < 10 years) after 96 weeks of HAART, despite adequate virologic control.
Much of the above data evaluated the growth of prepubertal HIV-infected children. However, the height achieved during the pubertal growth spurt can account for close to 20 % of fi nal adult height (FAH) (6) . Both the rate and the duration of pubertal growth are important determinants of overall statural gain (7) . Previous studies demonstrate pubertal delay in HIV-infected children with severe immunosuppression (8) . However, data regarding puberty in perinatally HIV-infected children with relatively good immunologic control are limited. It is likely that epigenetic factors, such as health, nutrition, and body mass index (BMI) infl uence the timing and duration of puberty (9) . Insulin-like growth factor binding protein 1 (IGFBP-1), a binding protein produced in the liver in response to proinfl ammatory cytokines (PIC), is increased in many catabolic states and has been shown to be inversely related to BMI in prepubertal HIV-infected children (10 -12) . Furthermore, IGFBP-1 can induce a state of growth hormone (GH) resistance by rendering insulin-like growth factor 1 (IGF-1), a growth-promoting polypeptide that mediates many of the anabolic actions of GH, unavailable to its receptors (11, 12) . Accordingly, IGFBP-1 inhibits both somatic linear growth and weight gain and has been described in association with growth failure in other chronic conditions, such as liver failure and juvenile rheumatoid arthritis (13 -15) . Specifi cally, in the children with liver failure, liver transplant led to decreased IGFBP-1 and increased height (13) . This is the fi rst study to evaluate the pubertal growth patterns and FAH in a predominantly non-Caucasian , inner city population of HIV-infected adolescents. We specifi cally evaluated both the timing and magnitude of peak growth velocity (GV) in this cohort. We hypothesized that worsening immunosuppression, suggesting increased viral mediated T-lymphocyte destruction, would lead to increased PIC, increased IGFBP-1, and subsequent GH resistance, as evidenced by decreased IGF-1 and IGFBP-3. This would be associated with poor growth and possible pubertal delay.
Patients and methods

Subjects
The Institutional Review Board of New York University School of Medicine approved this cross-sectional, retrospective analytical study. The study subjects consisted of 34 perinatally HIV-infected patients (19 males and 15 females) followed by the Pediatric Infectious Disease service and 12 HIV-exposed, uninfected (HEU) patients. The diagnosis of HIV was based on the detection of serum HIV antibodies and nucleic acid testing by polymerase chain reaction (PCR). The HEU patients were age-matched siblings, born to HIVinfected mothers, but who were determined to be HIV negative based on negative HIV antibodies and no evidence of HIV nucleic acid. Exclusion criteria included GH defi ciency, non-compensated thyroid disorder, cerebral palsy, glucocorticoid treatment for > 5 days, and chronic diseases, such as diabetes mellitus, cerebral palsy, or nonambulating patients. All patients had either attained FAH or fi nished the pubertal growth spurt.
Database
This was a cross-sectional retrospective study consisting of a chart review to determine patient ' s height, weight, BMI (kg/m 2 ), pubertal Tanner staging, menarchal history, laboratory data including viral load (VL) and CD4 + T-lymphocyte (CD4) count, and the use of HAART. Height, weight, and BMI SDS were based on the National Health and Nutrition Examination Survey data. Data were obtained between 1995 and 2010. A database which included demographic information (age, ethnicity, etc.) and the above data was created. Height was recorded annually beginning at 7 years of age. All height measurements were performed by trained nursing staff using the same scale with each measurement. The degree of accuracy of height measurements is within 0.3 cm. All patients with a complete data set were included in the study. The time of peak GV was identifi ed. This was correlated with Tanner staging, hormonal assays, and menarchal history when available. VL, CD4 count, and BMI were averaged over the period of peak growth. FAH was defi ned as a GV of less than 1 cm/year for a minimum of a 6-month period following the pubertal growth spurt.
Serum sample selection
Serum samples were previously obtained by the Pediatric Infectious Disease staff at routine offi ce visits and not during the time of intercurrent illness. Samples were stored in -70 ° F to -120 ° F freezers with minimal freeze-thaw cycles. A stored serum for each patient during the year of peak GV was identifi ed and analyzed for interleukin (IL)-1 α , IL-6, tumor necrosis factor (TNF), IGF-1, IGFBP-1, and IGFBP-3. A subset of patients (n = 5) had two serum samples analyzed -one during a period of good virologic control (VL log 10 < 3 copies/mL) and one during a period of poor virologic control (VL log 10 > 3 copies/mL). At least one sample was during the time of peak GV in this subset.
Viral/Immunologic control
HIV-infected patients were divided into two groups based on VL. Group I had VL log 10 < 3 copies/mL ( < 1000 copies/mL) and Group II had VL log 10 > 3 copies/mL ( > 1000 copies/mL). Patients ' degree of immunosuppression was determined based on CD4 count: < 200/ mm 3 severe immunosuppression, 200 -500/mm 3 moderate immunosuppression, and > 500/mm 3 no immunosuppression (16) .
Laboratory analysis
VL and lymphocyte subsets were determined using RNA PCR and fl ow cytometry, respectively. The quantifi cation of the cytokines IL-1 α , IL-6, and TNF-α and the growth factors IGF-1, IGFBP-1, and IGFBP-3 was determined using human multiplexing bead 
Statistical analysis
Statistical analysis was done using SPSS (IBM Corporation, New York, NY, USA). VL data were converted into log 10 data. Analytes below the limit of detection were assigned the following values: IL-1 α 3.0 pg/mL, IL-6 0.2 pg/mL, IGF-1 5 ng/mL, and IGFBP-1 0.012 pg/mL. Undetectable VL was assigned a value of 49 copies/mL. 
Results
Patient characteristics
Among the HIV-infected cohort, there were 15 females and 19 males (Table 2 ) . Of this cohort, 47 % were Hispanic, 47 % were African American, 2 % were mixed African American/ Hispanic, and 4 % were Caucasian. The average BMI was 19.7 kg/m 2 ( ± 3.38) for Group I (VL log 10 < 3 copies/mL) and 20.1 kg/m 2 ( ± 3.76) for Group II (VL log 10 > 3 copies/ mL) ( Table 2 ). There was no statistically signifi cant difference in BMI between Groups I and II. The mean VL log 10 of Groups I and II was 1.77 copies/mL ( ± 1.5) and 4.00 copies/mL ( ± 0.6), respectively ( Table 2) . Severe immunosuppression (CD4 < 200/mm 3 ) was found in 3 out of 34 patients (8 % ), moderate immunosuppression (CD4 200 -500/mm 3 ) in 12 out of 34 patients (35 % ), and no immunosuppression (CD4 > 500/mm 3 ) in 19 out of 34 patients (56 % ). There was no signifi cant difference in CD4 count between Groups I and II.
In Group I, 8 out of 11 patients (73 % ) were on HAART compared to 2 out of 23 patients (8 % ) in Group II (Table 2) (p ≤ 0.001).
Among the HEU (n = 12), 9 were female and 3 were male, 42 % were Hispanic, 50 % were African American, and 8 % were Caucasian. The average BMI of the HEU was 25.5 kg/ m 2 ( ± 6.9). The BMI of the HEU cohort was signifi cantly higher than the HIV-infected patients (p = 0.013).
FAH and pubertal parameters
There was a statistically signifi cant difference between the mean FAH SDS -0.78 ( ± 1.1) for the 34 HIV-infected cohort and -0.05 ( ± 0.78) for the 12 HEU (p = 0.034) (Figure 1 ) . Mean FAH SDS of the HIV-infected cohort was signifi cantly correlated with CD4 count (p = 0.019) (Figure 2 ), but not VL (p = 0.37).
In the HIV-infected patients, the mean age of peak GV was 13.4 years ( ± 1.9) and 10.7 years ( ± 1.3) for males and females, respectively. The age of peak GV was not statistically different (p = 0.58) based on VL ( Table 2 ). The overall mean peak GV was 9.6 cm/year ( ± 2.7) for Group I and 8.6 cm/ year ( ± 1.4) for Group II (p = 0.262). Males in Group I had a peak GV of 8.8 cm/year ( ± 2.4) and those in Group II had 9.35 cm/year ( ± 1.3) (p = 0.60). Among the females, peak GV was 10.64 cm/year ( ± 0.92) in Group I and 7.62 cm/year ( ± 2.97) in Group II (p = 0.08) ( Table 2 ). The timing and/or peak of GV did not correlate with CD4 count for both groups.
Cytokines
There were no signifi cant differences in cytokines based on VL or HIV status ( Table 3 ). The median IL-1 α was below the limit of detection for Group I, Group II, and the HEU. Of Group I patients, 18.1 % had detectable IL-1 α , 18.18 % of Group II had a detectable IL-1 α , and none of the HEU had a detectable IL-1 α . The median IL-6 was also below the limit of detection for Group I, Group II, and HEU. The median TNF-α was 5.72 pg/mL for Group I, 8.3 pg/mL for Group II, and 3.14 pg/mL for HEU (p = 0.234).
Growth factors
The mean IGF-1 was 159.6 ng/mL ( ± 185) for Group I, 210.1 ng/mL ( ± 154) for Group II, and 168.0 ng/mL ( ± 130) for HEU (p = 0.60). Of the subgroup with one serum sample during good control and one during poor control, the mean IGFBP-1 was 1.09 pg/mL during good control and 8.01 pg/mL during poor control. This was not statistically signifi cant. In one patient (patient X) with dramatic shift in the VL, the IGFBP-1 was 26 pg/mL when the VL was > 100,000 copies/mL and decreased to 1.275 pg/mL, with effective HAART decreasing the VL to < 50 copies/mL. At the same time, the IGF-1 increased from 5 to 200 ng/mL and the GV improved from 3 to 10 cm/year (Figure 3 ). There was no signifi cant difference between the cytokines (IL-1 α , IL-6, or TNF-α ) and growth factors (IGF-1 or IGFBP-3) in this subgroup between the sample with good control and that with poor control.
Discussion
This is the fi rst study to evaluate FAH and growth patterns in a predominantly non-Caucasian population of perinatally HIVinfected adolescents. Much of the research to date has been done with prepubertal children. We specifi cally evaluated the pubertal growth spurt to determine if alterations in this key growth parameter contributed to a shorter adult height in those with HIV infection. We confi rm the persistently decreased FAH compared to controls. The mean FAH SDS in our cohort was -0.78 ( ± 1.1) compared to a fi nal height SDS of 0.05 ( ± 0.78) in the HEU group (p = 0.034). The FAH was signifi cantly correlated with CD4 count, emphasizing the importance of good immunologic control in order to improve FAH.
A possible explanation for this direct correlation between immunologic control and FAH could be that increased viral mediated CD4 destruction leads to elevated cytokines and/ or a catabolic state, both resulting in increased IGFBP-1. We demon strated an inverse correlation between IGFBP-1 and both FAH and BMI. The HEU patients were taller than the HIV-infected patients, and only 25 % had detectable IGFBP-1. In contrast, the HIV-infected patients with the highest VL were the shortest, and 100 % had detectable IGFBP-1 (p = 0.0003). Furthermore, we found an inverse relationship between IGFBP-1 and BMI. Possibly due to small sample size, this did not reach signifi cance. As seen in patient X (Figure 3) , striking elevations in IGFBP-1 may only be seen in patients with considerable viremia leading to severe immunosuppression. Modest elevations in IGFBP-1, however, may be seen in patients with lower VL and better immune function. These modest elevations of IGFBP-1 may still have important physio logic implications, however, by inducing a certain level of GH resistance relative to controls.
We did not detect elevated serum cytokines; however, there may be others that we did not test for. As IGFBP-1 is produced in the liver in response to cytokines, it may be a HIV-infected patients are classifi ed as having " good control " (VL log 10 < 3 copies/mL) and " poor control " (VL log 10 > 3 copies/mL).
relatively more stable indirect indication of insidious cytokine elevation.
Our fi ndings suggest a normal timing of pubertal onset. A hallmark of puberty is the pubertal growth spurt; girls typically experience peak growth at breast Tanner stage 3 and boys at testicular Tanner stage 4 (17) . In a large multicenter study of 859 US adolescents, the mean age of Tanner 3 breast was 10.7 years (range 9.4 -12.7 years) in African American girls and the mean age of Tanner 4 testes was 12.8 years (range 10.7 -15.4 years) in African American boys (18) . Accordingly, in our study, the mean age of peak growth was 10.7 years ( ± 1.9) for girls and 13.4 years ( ± 1.3) for boys, which suggest physiologic pubertal timing. de Martino et al. (19) evaluated the time of pubertal onset in 212 perinatally infected, exclusively Caucasian, Italian patients. In contrast to our results, puberty was found to be delayed by approximately 2 years in girls and 1 year in boys (19) . Notably, the average BMI in our study was 19.7 kg/m 2 ( ± 3.38) for girls and 20.1 kg/m 2 ( ± 3.76) for boys compared to a median BMI of 16.5 kg/m 2 (95 % CI 14.0 -19.2) for HIV-infected girls and 16.0 kg/m 2 (95 % CI 13.6 -19.7) for HIV-infected boys in the de Martino et al. study (19) . Evidence suggests that the amount of body fat and the hormonal events of puberty are closely related (9) . Furthermore, in the Italian cohort, 40.1 % of the girls and 56.1 % of the boys were noted to have severe immunosuppression compared to < 8 % in our cohort (19) .
Data regarding the peak GV in HIV-infected patients are limited. We found a peak GV of 9.60 cm/year ( ± 2.7) and 8.62 cm/year ( ± 1.4) for Groups I and II, respectively. These results are similar to normative data for healthy children originally described by Marshall and Tanner (20) . This suggests that the magnitude of the peak GV is preserved. Our data did not permit analysis of the duration of the pubertal growth acceleration in our population.
Our study was limited by a relatively small sample size and the retrospective design, as sibling heights, midparental height data, birth weight, and Tanner staging were often not available. We were not able to obtain data on the timing and magnitude of the pubertal growth spurt in the HEU cohort. Furthermore, there are no age/gender-specifi c normative data for our analytes with Luminex.
Conclusions
Our study demonstrates shorter FAH in HIV patients compared to controls, despite normal timing and magnitude of the pubertal growth spurt. Thus, any negative impact of HIV infection on height likely occurs in the prepubertal period. We found a signifi cant correlation between CD4 count and FAH, suggesting that deteriorating immune function adversely affects height. Larger prospective trials should be done to further evaluate the timing, magnitude, and duration of the pubertal growth spurt in HIV-infected adolescents. Furthermore, the relationship of IGFBP-1 with growth and BMI should be further explored, as this could lead to alternative treatments, such as anticytokine therapy to improve the growth of perinatally infected children. 
